ID   SMOV-2
AC   CVCL_S920
SY   SMOV2
DR   Cosmic; 2482701
DR   GEO; GSM416683
DR   Wikidata; Q54954981
RX   PubMed=10695021;
RX   PubMed=20081105;
CC   Population: Japanese.
CC   Doubling time: 48.2 hours (PubMed=10695021).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 10-04-25; Version: 11
//
RX   PubMed=10695021;
RA   Yonamine K., Hayashi K., Iida T.;
RT   "Establishment and characterization of human ovarian clear cell
RT   adenocarcinoma cell line (SMOV-2), and its cytotoxicity by anticancer
RT   agents.";
RL   Hum. Cell 12:139-148(1999).
//
RX   PubMed=20081105; DOI=10.1210/me.2009-0295; PMCID=PMC2817607;
RA   Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H.,
RA   Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M.,
RA   Anderson M.L., Matzuk M.M.;
RT   "A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.";
RL   Mol. Endocrinol. 24:447-463(2010).
//